Business Description
WAVE Life Sciences Ltd
ISIN : SG9999014716
Total Employee Number:
317Description
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 34.65 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 6.25 | |||||
Beneish M-Score | -2.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 76.5 | |||||
3-Year EBITDA Growth Rate | 14.1 | |||||
3-Year EPS without NRI Growth Rate | 14.9 | |||||
3-Year FCF Growth Rate | 12 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 37.48 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.23 | |||||
9-Day RSI | 42.67 | |||||
14-Day RSI | 44.34 | |||||
3-1 Month Momentum % | -18.9 | |||||
6-1 Month Momentum % | -55.98 | |||||
12-1 Month Momentum % | -22.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.26 | |||||
Quick Ratio | 11.26 | |||||
Cash Ratio | 10.93 | |||||
Days Sales Outstanding | 18.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.2 | |||||
Shareholder Yield % | -41.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -274.21 | |||||
Net Margin % | -255.7 | |||||
EBITDA Margin % | -261.68 | |||||
FCF Margin % | -257.4 | |||||
OCF Margin % | -256.02 | |||||
ROE % | -62.63 | |||||
ROA % | -45.8 | |||||
ROIC % | -229.24 | |||||
3-Year ROIIC % | 2006.97 | |||||
ROC (Joel Greenblatt) % | -891.33 | |||||
ROCE % | -61.58 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 15.12 | |||||
PB Ratio | 2.19 | |||||
Price-to-Tangible-Book | 2.19 | |||||
EV-to-EBIT | -3 | |||||
EV-to-EBITDA | -3.15 | |||||
EV-to-Revenue | 8.23 | |||||
EV-to-Forward-Revenue | 14.7 | |||||
EV-to-FCF | -3.19 | |||||
Price-to-GF-Value | 1.35 | |||||
Price-to-Median-PS-Value | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 2.29 | |||||
| Price-to-Net-Cash | 2.37 | |||||
Earnings Yield (Greenblatt) % | -33.33 | |||||
FCF Yield % | -16.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
WAVE Life Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 61.834 | ||
| EPS (TTM) (€) | -0.91 | ||
| Beta | 0.8632 | ||
| 3-Year Sharpe Ratio | 0.52 | ||
| 3-Year Sortino Ratio | 1.19 | ||
| Volatility % | 150.45 | ||
| 14-Day RSI | 44.34 | ||
| 14-Day ATR (€) | 0.251212 | ||
| 20-Day SMA (€) | 5.242 | ||
| 12-1 Month Momentum % | -22.56 | ||
| 52-Week Range (€) | 4.58 - 17.6 | ||
| Shares Outstanding (Mil) | 192.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
WAVE Life Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
WAVE Life Sciences Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-10 08:30 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-10 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:30 | In 13 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | In 12 days | ||
| Goldman Sachs 47(th) Annual Global Healthcare Conference | 2026-06-08 08:00 | 4.88 (-6.15%) | ||
| Guidance call for 2026 | 2026-06-03 10:30 | 4.82 (-9.06%) | ||
| Guidance call for 2026 | 2026-05-20 08:00 | 5.50 (-3.51%) | ||
| RNA Editing for AATD Interim RestorAATion-2 Clinical Data | 2026-05-18 17:30 | 5.80 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-04-28 08:30 | 5.90 (-1.67%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 5.90 (-1.67%) |
Show
Entries
WAVE Life Sciences Ltd Frequently Asked Questions
What is WAVE Life Sciences Ltd(STU:1U5)'s stock price today?
The current price of STU:1U5 is €5.05. The 52 week high of STU:1U5 is €17.60 and 52 week low is €4.58.
When is next earnings date of WAVE Life Sciences Ltd(STU:1U5)?
The next earnings date of WAVE Life Sciences Ltd(STU:1U5) is 2026-07-30 Est..
Does WAVE Life Sciences Ltd(STU:1U5) pay dividends? If so, how much?
WAVE Life Sciences Ltd(STU:1U5) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| ADDF and AFTD Partner to Support Wave Life Sciences' FTD and ALS Clinical Program | 2022-01-25 |
Articles on WAVE Life Sciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers